Predictive Oncology Inc., a US-based firm, is leveraging artificial intelligence (AI) to develop cancer therapies. The knowledge-driven company operates through four segments including Helomics, zPREDICTA, Soluble, and Skyline. Through Helomics, the firm offers AI predictive models of tumor drug response to enhance clinical outcomes for patients. Meanwhile, the zPREDICTA segment has developed organ-specific disease models which 3D reconstruct human tissues representing each disease state to mimic drug response for anticancer agents. The Soluble segment provides services using a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. Additionally, the Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which helps to eliminate the exposure to infectious fluids found in the healthcare environment. The firm was formerly known as Precision Therapeutics Inc. before rebranding in June 2019. Predictive Oncology Inc. was established in 2002 and is headquartered in Eagan, Minnesota.